96. Crohn disease Clinical trials / Disease details
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04804046 (ClinicalTrials.gov) | July 15, 2021 | 11/3/2021 | Synbiotics and Post-op Crohn's Disease | Defining Microbial and Immune Changes Following Synbiotic Supplementation in Post-operative Crohn's Disease Patients | Crohn's Disease | Dietary Supplement: Synbiotic;Other: Digestible Maltodextrin | University of Alberta | W. Garfield Weston Foundation | Recruiting | 18 Years | 75 Years | All | 36 | N/A | Canada |
| 2 | NCT00305409 (ClinicalTrials.gov) | June 2006 | 20/3/2006 | Synbiotic Treatment in Crohn's Disease Patients | Synbiotic Treatment in Crohn's Disease Patients | Crohn's Disease | Drug: Synbiotic (Synergy I / B.longum) | University of Dundee | NULL | Completed | 18 Years | 79 Years | Both | 50 | N/A | United Kingdom |
| 3 | NCT00587041 (ClinicalTrials.gov) | February 2006 | 21/12/2007 | Use of Oral Probiotics to Reduce Urinary Oxalate Excretion | Use of Oral Probiotics to Reduce Urinary Oxalate Excretion | Nephrolithiasis;Hyperoxaluria;Crohn's Disease | Dietary Supplement: Oxadrop;Dietary Supplement: Agri-King Synbiotic (AKSB);Other: Placebo | Mayo Clinic | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institutes of Health (NIH);National Center for Complementary and Integrative Health (NCCIH);National Center for Research Resources (NCRR) | Completed | 18 Years | N/A | All | 40 | Phase 1/Phase 2 | United States |